Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis

被引:85
作者
Guillemin, GJ [1 ]
Smith, DG
Kerr, SJ
Smythe, GA
Kapoor, V
Armati, PJ
Brew, BJ
机构
[1] St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia
[2] St Vincents Hosp, Dept Neurol, Sydney, NSW 2010, Australia
[3] St Vincents Hosp, Dept HIV Med, Sydney, NSW 2010, Australia
[4] Univ New S Wales, Ray Williams Biomed Mass Spectrometry Facil, Sydney, NSW, Australia
[5] Univ New S Wales, Sch Physiol & Pharmacol, Fac Med, Sydney, NSW, Australia
[6] Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia
关键词
D O I
10.1179/135100000101535375
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The role of astrocytes in the production of the neurotoxin quinolinic acid (QUIN) and other products of the kynurenine pathway (KP) is controversial. Using cytokine-stimulated human astrocytes, we assayed key enzymes and products of the KP. We found that astrocytes lack kynurenine-hydroxylase so that large amounts of kynurenine (KYN) and kynurenic acid (KYNA) were produced, while minor amounts of QUIN were synthesised that were completely degraded. We then showed that kynurenine added to macrophages led to significant production of QUIN. These results suggest that astrocytes alone are neuroprotective by minimising QUIN production and maximising synthesis of KYNL. However, it is likely that, in the presence of macrophages and/or microglia, astrocytes are neurotoxic by producing large concentrations of KYN that can be metabolised by neighbouring monocytic cells to QUIN.
引用
收藏
页码:108 / 111
页数:4
相关论文
共 10 条
[1]
Chemistry and neurochemistry of the kynurenine pathway of tryptophan metabolism [J].
Botting, NP .
CHEMICAL SOCIETY REVIEWS, 1995, 24 (06) :401-&
[2]
How HIV leads to neurological disease [J].
Brew, BJ ;
Wesselingh, SL ;
Gonzales, M ;
Heyes, MP ;
Price, RW .
MEDICAL JOURNAL OF AUSTRALIA, 1996, 164 (04) :233-234
[3]
Curzon G, 1996, ADV EXP MED BIOL, V398, P27
[4]
Guillemin G, 1997, J NEUROSCI RES, V49, P576, DOI 10.1002/(SICI)1097-4547(19970901)49:5<576::AID-JNR8>3.3.CO
[5]
2-O
[6]
Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types [J].
Heyes, MP ;
Chen, CY ;
Major, EO ;
Saito, K .
BIOCHEMICAL JOURNAL, 1997, 326 :351-356
[7]
KYNURENIC ACID, AN ENDOGENOUS GLUTAMATE ANTAGONIST, IN SHR AND WKY RATS - POSSIBLE ROLE IN CENTRAL BLOOD-PRESSURE REGULATION [J].
KAPOOR, V ;
KAPOOR, R ;
CHALMERS, J .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1994, 21 (11) :891-896
[8]
Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages [J].
Kerr, SJ ;
Armati, PJ ;
Pemberton, LA ;
Smythe, G ;
Tattam, B ;
Brew, BJ .
NEUROLOGY, 1997, 49 (06) :1671-1681
[9]
STONE TW, 1993, PHARMACOL REV, V45, P309
[10]
Kynurenine aminotransferase I (KATI) isoform gene expression in the rat brain:: an in situ hybridization study [J].
Tamburin, M ;
Mostardini, M ;
Benatti, L .
NEUROREPORT, 1999, 10 (01) :61-65